V-Wave nabs FDA breakthrough designation for its heart pressure shunt implant

E-Tattoo takes the hassle out of heart monitoring
Currently, V-Wave’s device is being evaluated in a randomized trial set to enroll 500 patients with advanced heart failure. (Pixabay)

V-Wave has received a breakthrough device designation from the FDA for its interatrial shunt being tested for heart failure.

Implanted through a minimally invasive procedure, the biocompatible device creates a passageway connecting the heart’s two atria. By allowing excess blood to flow between the chambers, the shunt is designed to help regulate high pressure in the left atrium, which can lead to the buildup of fluid in the lungs and difficulty breathing.

Currently, V-Wave’s device is being evaluated in a randomized trial set to enroll 500 patients with advanced heart failure that are still symptomatic following other drug and device therapies, including patients with preserved or reduced left ventricular ejection fraction. The study is expected to return data in late 2021.

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

In addition to the extra face time with federal regulators that the FDA designation affords during development and prioritized review, the Centers for Medicare and Medicaid Services recently finalized ways to expedite reimbursement for breakthrough products following approval.

RELATED: V-Wave nets $70M in Series C financing for its heart shunt device

“The potential for early CMS support for this program makes our Breakthrough Designation a double-win for [heart failure] patients who need access to novel therapies as quickly as possible,” V-Wave CEO Neal Eigler said in a statement.

The Israel-based V-Wave raised $70 million for its efforts last year, in a series C round led by Deerfield Management. Its previous backers also include Johnson & Johnson Innovation and Edwards Lifesciences.

"More than 6 million people suffer from chronic heart failure in the US. HF remains a leading cause of acute hospitalization in the Medicare age group,” said William Abraham, V-Wave’s chief medical officer.

“Despite decades of advances in therapy, heart failure patients continue to deteriorate, enduring disabling symptoms, having a poor quality of life, diminished exercise tolerance, and a markedly reduced life expectancy,” Abraham said, pointing to fluid buildup in the lungs as one of the most common reasons for heart failure hospitalizations.

Suggested Articles

Memorial Sloan Kettering Cancer Center’s digital cancer pathology spinout, Paige, has secured an additional $15 million from Goldman Sachs.

The world has changed since Thermo Fisher Scientific reached a hard-fought, $11.5 billion agreement to acquire Qiagen in early March.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.